Details

Autor(en) / Beteiligte

• Rout, Ajaya Kumar
• Dehury, Budheswar
• Parida, Satya Narayan
• Rout, Sushree Swati
• Jena, Rajkumar
• Kaushik, Neha
• Kaushik, Nagendra Kumar
• Pradhan, Sukanta Kumar
• Sahoo, Chita Ranjan
• Singh, Ashok Kumar
• Arya, Meenakshi
• Behera, Bijay Kumar

Titel

A review on structure-function mechanism and signaling pathway of serine/threonine protein PIM kinases as a therapeutic target

Ist Teil von

• International journal of biological macromolecules, 2024-06, Vol.270 (Pt 1), p.132030-132030, Article 132030

Ort / Verlag

Netherlands: Elsevier B.V

Erscheinungsjahr

2024

Link zum Volltext

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• The proviral integration for the Moloney murine leukemia virus (PIM) kinases, belonging to serine/threonine kinase family, have been found to be overexpressed in various types of cancers, such as prostate, breast, colon, endometrial, gastric, and pancreatic cancer. The three isoforms PIM kinases i.e., PIM1, PIM2, and PIM3 share a high degree of sequence and structural similarity and phosphorylate substrates controlling tumorigenic phenotypes like proliferation and cell survival. Targeting short-lived PIM kinases presents an intriguing strategy as in vivo knock-down studies result in non-lethal phenotypes, indicating that clinical inhibition of PIM might have fewer adverse effects. The ATP binding site (hinge region) possesses distinctive attributes, which led to the development of novel small molecule scaffolds that target either one or all three PIM isoforms. Machine learning and structure-based approaches have been at the forefront of developing novel and effective chemical therapeutics against PIM in preclinical and clinical settings, and none have yet received approval for cancer treatment. The stability of PIM isoforms is maintained by PIM kinase activity, which leads to resistance against PIM inhibitors and chemotherapy; thus, to overcome such effects, PIM proteolysis targeting chimeras (PROTACs) are now being developed that specifically degrade PIM proteins. In this review, we recapitulate an overview of the oncogenic functions of PIM kinases, their structure, function, and crucial signaling network in different types of cancer, and the potential of pharmacological small-molecule inhibitors. Further, our comprehensive review also provides valuable insights for developing novel antitumor drugs that specifically target PIM kinases in the future. In conclusion, we provide insights into the benefits of degrading PIM kinases as opposed to blocking their catalytic activity to address the oncogenic potential of PIM kinases. •PIM kinases, members of serine/threonine kinase family are overexpressed in different types of cancers.•Tumorigenic phenotypes like proliferation and survival are controlled by phosphorylation of substrates.•The three isoforms of PIM kinases exhibit significant sequence and structural similarity.•Structure-based approaches combined with AI can scale up PIM kinase oncological drug discovery.•PROTACs offer promising weapon to tackle drug resistance in PIM Kinases by facilitating degradation of the target.